UK-based Albert Labs announces its official trading date on Canada's CSE exchange. The Company will commence trading Thursday, March 11th under the symbol "ABRT"
Articles
Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies
Incannex reports a strong clinical response in its trial of a cannabinoid combination product IHL-42X for sleep apnea.
The Biden Strategy On Mental Health: Lots Of Bandaids, No Substance
With a mental health catastrophe in the United States spiraling out of control, the Biden "plan" is just more of what has failed.
Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder
Novamind announces it will conduct a Phase II clinical trial for the sponsor, Usona Institute, on a psilocybin-based therapy for MDD.
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics
Incannex Healthcare to incorporate virtual reality in a new R&D partnership aimed at psychedelics-based therapies.
Apex Labs granted phase 2a Clinical Trial Application approval by Health Canada for treatment of PTSD in Veterans
Apex has secured its Veteran patient base, clinical trial location and Qualified Investigator for its phase 2a program expected to launch as early as Q2/Q3 2022.
Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update
Seelos Therapeutics reports progress on several of its drug R&D initiatives, including preparing for a Phase IIb/Phase III trial of SLS-005 for ALS.
GOP Missouri Lawmaker Files Psychedelics Therapy And Decriminalization Bill
A Missouri Republican lawmaker filed a bill on Tuesday that would legalize a wide range of psychedelics for therapeutic use at designated care facilities while further decriminalizing low-level possession in general.
Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care
Field Trip Health announces a strategic partnership with Cerebral, "the fastest growing online mental health platform".
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program
MINDCURE announces new formulations for its proprietary synthetic ibogaine, supported by a new patent application.
Revitalist and PharmaTher Announce Collaboration to Develop and Advance Novel and Standardized Ketamine Treatment Protocols for Mental Health Disorders and Chronic Pain Syndromes
Revitalist and Pharmather to collaborate on novel and standardized treatment protocols for for ketamine-based psychotherapy.
MindMed Announces Publication of Study Comparing the Acute Effects of LSD and Psilocybin in Healthy Subjects
MindMed announced the peer-reviewed publication of a study directly comparing the acute effects of LSD and psilocybin in healthy subjects.
MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects
MindMed releases a peer-reviewed study that confirms the similar psychoactive effects of psilocybin and Lysergic Acid Diethylamide (LSD).
Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights
Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.
Red Light Holland Reports Fiscal Third Quarter Results
Red Light Holland reports quarterly revenue growth of 28% and gross profit growth of 48% for Q3 of fiscal 2022. Strong cash position of CAD$27.3 million.